Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2022 | $5.00 → $2.00 | Buy | BTIG |
| 12/20/2021 | $8.00 → $2.50 | Buy | Chardan Capital |
| 12/16/2021 | $2.00 | Buy | HC Wainwright & Co. |
| 9/15/2021 | $5.00 | Buy | BTIG |
8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously
Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously
HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00
Building on proven targeting of the FHAB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC construct designated – SON-5010 showed similar activities as compared with Kadcyla® and also trastuzumab-MMAE, in a preclinical study Company's ADC Platform offers the potential for novel ADCs with homogeneous structural integrity, tumor targeting domain, interchangeability of toxin payloads and flexible conjugation site usage Management releases "What This Means" segment discussing its ADC platform; Access here PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW Marriott in Los Angeles, CA. Details of the poster presentation are as follows: Session: Poster Session BAbstract title: Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and enhances therapeutic efficac
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa
Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan
PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021. "I am pleased to welcome Richard and Manuel to Sonnet at such an exciting time as we prepare to enter SON-1010, our proprietary fully human Interleukin 12 (IL-12) therapeutic candidate configured with our Fully Human Albumin Binding (FHAB) technology, into the clinic," said Pankaj Mohan, Ph.D., Founder and CEO. "Richard is a seasoned